Physician profile
Jesse Ezzell
NPI 1912911843
$4,199.84
in general payments reported to CMS, 2019-2025
34 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $398 · 2021: $894 · 2022: $791 · 2023: $302 · 2024: $598 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,355.95 | 2019-2025 | |
| Janssen Biotech, INC. | $721.07 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.05 | 2019-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $234.46 | 2019-2025 | |
| Madrigal Pharmaceuticals | $184.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $135.73 | 2019-2024 | Entyvio |
| Nestle Healthcare Nutrition INC. | $122.97 | 2021-2023 | |
| Celgene Corporation | $101.78 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $96.40 | 2019-2025 | |
| Ardelyx, INC. | $79.98 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $74.35 | 2021-2023 | Dificid |
| Aimmune Therapeutics, INC. | $73.02 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $63.99 | 2020-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $62.76 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $62.39 | 2024 | Dupixent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $51.62 | 2022-2024 | |
| Boston Scientific Corporation | $51.10 | 2019 | |
| Allergan, INC. | $50.03 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $45.98 | 2021-2022 | |
| Pfizer INC. | $39.54 | 2019-2025 | |
| Celltrion USA INC. | $35.49 | 2024-2025 | Vegzelma |
| Echosens North America, INC. | $32.30 | 2024 | Fibroscan |
| Phathom Pharmaceuticals, INC. | $28.22 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $27.10 | 2021-2022 | |
| Shire North American Group INC | $26.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.86 | 2020 | |
| Daiichi Sankyo INC. | $22.07 | 2022 | |
| Adamas Pharmaceuticals, INC. | $22.00 | 2020 | |
| Lilly USA, LLC | $20.89 | 2025 | Omvoh |
| Ucb, INC. | $19.74 | 2019 | |
| Capsovision, INC. | $16.46 | 2025 | Capsocam Plus |
| Concordia Pharmaceuticals INC. | $14.92 | 2019 | |
| Axonics, INC. | $14.38 | 2022 | |
| Braintree Laboratories, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Ezzell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.